Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Norris Medicines Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Option Chain
Analyzes market sentiment, predicts Norris Medicines Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Norris Medicines posts Q4 net loss of Rs 0.23 cr
-
Norris Medicines - Outcome Of The Board Meeting Held On May 28, 2025_Pursuant To Regulation 30 And Regulation 33 Of The SEBI
-
Norris Medicines - Board Meeting Outcome for Outcome Of The Board Meeting Held On May 28, 2025_Pursuant To Regulation 30 And
-
Norris Medicines - Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Req
-
Norris Medicines - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Norris Medicines has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Norris Medicines - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Key fundamentals
Evaluate the intrinsic value of Norris Medicines Ltd stock
| Name | March-24 | March-23 | March-22 | March-21 | March-20 |
|---|---|---|---|---|---|
| Assets | 4.9617 | 5.9819 | 7.4071 | 8.0927 | 12.5147 |
| Liabilities | 4.9617 | 5.9819 | 7.4071 | 8.0927 | 12.5147 |
| Equity | 9.9257 | 9.9257 | 9.9257 | 9.9257 | 9.9257 |
| Gross Profit | -0.1849 | 0.9223 | -0.0718 | -1.7444 | -2.1551 |
| Net Profit | -1.1867 | -1.7494 | -3.2634 | -4.9619 | -2.8411 |
| Cash From Operating Activities | 0.1697 | 1.1995 | -1.0094 | 1.1135 | -2.8836 |
| NPM(%) | -21.05 | -20.93 | -34.57 | -40.5 | -36.22 |
| Revenue | 5.6356 | 8.3581 | 9.4384 | 12.2511 | 7.8437 |
| Expenses | 5.8205 | 7.4358 | 9.5102 | 13.9955 | 9.9988 |
| ROE(%) | 8.02 | 11.82 | 22.06 | 33.54 | 19.2 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Norris Medicines Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 859.90 | 1.12 | 28.38 | 11.27 | 301.39 | 0.58 |
| Lotus Eye Hospital and Institute Ltd | 72.27 | -2.54 | 207.09 | 41.05 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 26.00 | 1.13 | 0.00 | 85.24 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 806.15 | -0.38 | 0.00 | 38.71 | -687.10 | 0.00 |
Company Info
Norris Medicines Limited was established as a private limited company in the state of Maharashtra on 7th September 1990. The company commenced commercial operations in November 1991 with the commissioning of the formulations unit. The unit was set up at a total capacity outlay of Rs 135.85 lakhs, which was financed by equity contribution from the promoters and associates to the extent of Rs 108.12 lakhs and term loan of Rs 27.73 lakhs from Gujarat State Finance Corporation. Norris was converted into a public limited company with effect from 7th March 1992. 1990 Launch of Norris 1992 Launch of Ethical Division and conversion of company into Public Limited company 1994 WHO cGMP Certificate 1995 Major Expansions 1996 Started exporting to European, Middle East, Far East and African Countries 2000 The Company has decided to issue 1,80,00,000 No. of equity shares of Rs. 10 each on preferential/private placement basis at a price not less than Rs. 10 per share to PHC Holdings Ltd., 90,00,000 shares and Positive Healthcare (Asia) Ltd. 2006 -Launching of Diabetic & Cardiac products 2007 - Launching of Dental product range 2012 -Launching of New Molecule Tolperisone with Paracetamol tablet 2013 -Extension in Anti malarial range with Artemether Lumefantrine tablet & dry syrup
Norris Medicines Limited was established as a private limited company in the state of Maharashtra on 7th September 1990. The company commenced commercial operations in November 1991 with the commissioning of the formulations unit. The unit was set up at a total capacity outlay of Rs 135.85 lakhs, which was financed by equity contribution from the promoters and associates to the extent of Rs 108.12 lakhs and term loan of Rs 27.73 lakhs from Gujarat State Finance Corporation. Norris was converted into a public limited company with effect from 7th March 1992. 1990 Launch of Norris 1992 Launch of Ethical Division and conversion of company into Public Limited company 1994 WHO cGMP Certificate 1995 Major Expansions 1996 Started exporting to European, Middle East, Far East and African Countries 2000 The Company has decided to issue 1,80,00,000 No. of equity shares of Rs. 10 each on preferential/private placement basis at a price not less than Rs. 10 per share to PHC Holdings Ltd., 90,00,000 shares and Positive Healthcare (Asia) Ltd. 2006 -Launching of Diabetic & Cardiac products 2007 - Launching of Dental product range 2012 -Launching of New Molecule Tolperisone with Paracetamol tablet 2013 -Extension in Anti malarial range with Artemether Lumefantrine tablet & dry syrup
Read More
Parent Organisation
Norris Medicines Ltd.
Founded
07/09/1990
Managing Director
Mr.Vimal Shah
NSE Symbol
FAQ
The current price of Norris Medicines Ltd is
The 52-week high for Norris Medicines Ltd is
The market capitalization of Norris Medicines Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Norris Medicines Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Norris Medicines Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Norris Medicines Ltd shares.
The CEO of Norris Medicines Ltd is Mr.Vimal Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
